Morphine tolerance in mice changes response of heroin from μ to δ opioid receptors

Proceedings of the Society for Experimental Biology and Medicine

Volumn 224, Issue 2, 2000, Pages 93-101

  Rady, Jodie J ^a,c   Holmes, Blythe B ^a   Portoghese, Philip S ^b   Fujimoto, James M ^a,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICUCULLINE; DELTA OPIATE RECEPTOR; DIAMORPHINE; MORPHINE; MU OPIATE RECEPTOR; NALTRIBEN; NALTRINDOLE; OPIATE ANTAGONIST; PICROTOXIN; PLACEBO;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; MOUSE; NONHUMAN; RECEPTOR INTRINSIC ACTIVITY; TAIL FLICK TEST;

ANIMALIA;

EID: 0034069774     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1373.2000.22406.x     Document Type: Article

References (48)

1. Way EL. Brain uptake of morphine: Pharmacolgical implications. Fed Proc 26:1115-1118, 1967.
2. Way EL, Young JM, Kemp JW. Metabolism of heroin and its pharmacologic implications. Bull Narc 17:25-33, 1965.
3. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin S-U, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 310:1213-1217, 1984.
4. Oldendorf WM, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178:984-986, 1972.
5. Martin WR, Frazer HF. A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J Pharmacol Exp Ther 133:388-399, 1961.
6. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 3:773-776, 1983.
7. Rady JJ, Elmer GI, Fujimoto JM. Opioid receptor selectivity of heroin given intracerebroventricularly differs in six strains of inbred mice. J Pharmacol Exp Ther 288:438-445, 1999.
8. Rady JJ, Roerig SC, Fujimoto JM. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception. J Pharmacol Exp Ther 256:448-457, 1991.
9. Rady JJ, Aksu F, Fujimoto JM. The heroin metabolite, 6-monoacetylmorphine, activates δ opioid receptors to produce antinociception in Swiss Webster mice. J Pharmacol Exp Ther 266:1222-1231, 1994.
10. Rady JJ, Gorny J, Fujimoto JM. Heroin antinociception changed from μ to δ receptor in streptozotocin-treated mice. Jpn J Pharmacol 78:443-454, 1998.
11. Lange DG, Roerig SC, Fujimoto JM, Wang RIH. Absence of cross-tolerance to heroin in morphine-tolerant mice. Science 208:72-74, 1980.
12. 5]enkephalin, a δ opioid agonist, given intracerebroventricularly in the mouse produces antinociception through mediation of spinal GABA receptors. Pharmacol Biochem Behav 49:675-682, 1994.
13. Rady JJ, Fujimoto JM. Spinal GABA receptors mediate brain δ opioid analgesia in Swiss Webster mice. Pharmacol Biochem Behav 51:655-659, 1995.
14. A receptors. Pharmacol Biochem Behav 54:363-369, 1996.
15. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79, 1941.
16. Dewey WL, Harris LS, Howes JF, Nuite JA. The effect of various neurohormonal modulators on the activity of morphine and the narcotic antagonists in the tail flick and phenylquinone test. J Pharmacol Exp Ther 175:435-142, 1970.
17. Brown GP, Yang K, King MA, Rossi GC, Leventhal L, Chang A, Pasternak GW. 3-Methoxynaltrexone, a selective heroin/morphine-6β-glucuronide antagonist. FEBS Lett 412:35-38, 1997.
18. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, Pasternak GW. Antisense mapping of MOR-1 in rats: Distinguishing between morphine and morphine-6β-glucuronide antinociception. J Pharmacol Exp Ther 281:109-114, 1997.
19. Rossi GC, Brown GP, Leventhal L, Yang K, Pasternak GW. Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesia. Neurosci Lett 216:1-4, 1996.
20. Haley TJ, McCormick WG. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12:12-15, 1957.
21. Rady JJ, Takemori AE, Portoghese PS, Fujimoto JM. Supraspinal δ receptor subtype activity of heroin and 6-monoacetylmorphine in Swiss Webster mice. Life Sci 55:603-609, 1994.
22. Hylden JL, Wilcox GL. Intrathecal morphine in mice: A new technique. Eur J Pharmacol 167:313-316, 1980.
23. Litchfield JT, Wilcoxon F. A simplified method for evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113, 1949.
24. Steel RGD, Torrie JH. Principles and Procedures of Statistics with Special Reference to the Biological Sciences. New York: McGraw-Hill Book Company, Inc., pp99-111, 1960.
25. Portoghese PS, Sultana M, Nagase H, Takemori AE. Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid antagonists. J Med Chem 31:281-282, 1988.
26. 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol 218:195-196, 1992.
27. Wigdor S, Wilcox GL. Central and systemic morphine-induced antinociception in mice: Contribution of descending serotonergic and noradrenergic pathways. J Pharmacol Exp Ther 242:90-95, 1987.
28. Arts KS, Holmes BB, Fujimoto JM. Morphine and D-Ala-N-methyl-Phe-Gly-ol activates descending noradrenergic and serotonergic antinociceptive systems to different degrees. J Pharmacol Exp Ther 257:890-896, 1991.
29. 2 opioid actions. Life Sci 48:2005-2011, 1991.
30. Pick CG, Nejat RJ, Pasternak GW. Independent expression of two pharmacologically distinct supraspinal μ analgesic systems in genetically different mouse strains. J Pharmacol Exp Ther 265:166-171, 1993.
31. Zaki PA, Bilsky EJ, Evans CJ, Porreca F. Opioid receptor types and subtypes: The δ receptors as a model. Annu Rev Pharmacol Toxicol 36:379-401, 1996.
32. Roerig SC, Fujimoto JM. Morphine antinociception in different strains of mice: Relationship of supraspinal-spinal multiplicative interaction to tolerance. J Pharmacol Exp Ther 247:603-608, 1988.
33. Simon GS, Dewey WL. Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther 218:318-323, 1991.
34. 2-opioid receptors. Neurosci Lett 165:141-143, 1994.
35. 2-opioid receptors. Life Sci 55:121-126, 1994.
36. Holmes BB, Rady JJ, Fujimoto JM. Heroin acts on δ opioid receptors in the brain of streptozotocin-induced diabetic rats. Proc Soc Exp Biol Med 218:334-340, 1998.
37. 5]enkephalin binding sites by different mechanisms. Neuropharmacology 27:965-974, 1988.
38. Holaday J. Upregulation of the μ-noncompetitive δ binding site by chronic morphine administration: Effect of preincubating membranes in 400 nM sodium chloride. NIDA Res Monogr 75:93-96, 1986.
39. Rothman RB, Danks JA, Jacobson AE, Burke TR Jr., Rice KC, Tortella FC, Holaday JW. Morphine tolerance increases μ-noncompetitive δ binding sites. Eur J Pharmacol 124:113-119, 1986.
40. Rothman RB, Long JB, Bykov V, Xu H, Jacobson AE, Rice KC, Holaday JW. Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence. Peptides 12:151-160, 1991.
41. Yukhanov RY, Klodt PM, Il'ina D, Zaitsev SV, Maisky AI. Opiate withdrawal intensity correlated with presence of DSLET high-affinity binding. Pharmacol Biochem Behav 49:1109-1112, 1994.
42. Takemori AE, Portoghese PS. Evidence for the interaction of morphine with κ and δ opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J Pharmacol Exp Ther 243:91-97, 1987.
43. Lange DG, Roerig SC, Fujimoto JM, Busse LW. Withdrawal tolerance and unidirectional non-cross tolerance in narcotic pellet implanted mice. J Pharmacol Exp Ther 224:13-20, 1983.
44. Paktor J, Vaught JL. Differential analgesic cross-tolerance to morphine between lipophilic and hydrophilic narcotic agonists. Life Sci 34:13-21, 1983.
45. Patrick GA, Dewey WL, Spaulding TC, Harris LS. Relationship of brain morphine levels to analgesic activity in acutely treated mice and rats and in pellet implanted mice. J Pharmacol Exp Ther 193:876-883, 1975.
46. Sofuoglu M, Portoghese PS, Takemori AE. Differential antagonism of δ opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for δ opioid receptor subtypes. J Pharmacol Exp Ther 257:676-680, 1991.
47. Lange DG, Roerig SC, Fujimoto JF, Wang RI. Enhancement of etorphine brain concentrations and changes in etorphine-naloxone pA2 values in morphine-pretreated mice. Biochem Pharmacol 30:147-155, 1981.
48. Tulunay FC, Takemori AE. The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J Pharmacol Exp Ther 190:395-400, 1974.